A recent large, randomized controlled trial (coauthored by Friedman School Dean and Tufts Health & Nutrition Letter editor-in-chief Dariush Mozaffarian, MD, DrPH) evaluated the impact of a new omega-3 fatty acid supplement on cardiovascular health. The researchers tested the high-dose (4 grams/day) prescription-only formulation of omega-3 fatty acids in patients who were on statins, had […]
To continue reading this article or issue you must be a paid subscriber
Subscribe to Tufts Health & Nutrition
Get the next year of Tufts Health & Nutrition for as little as $18. And access all of our back issues and online content free of charge.
Subscribe today and save 36% off the regular rate!
Already Subscribed?
Click Here to Sign In |
Forgot your password? |
Activate Web Access
 evaluated the impact of a new omega-3 fatty acid supplement on cardiovascular health. The researchers tested the high-dose (4 grams/day) prescription-only formulation of omega-3 fatty acids in patients who were on statins, had high blood triglyceride levels and low HDL-cholesterol, and had or were at high risk for cardiovascular disease.){kind=link}
